Poor
Not Aligned
Patient Risk:
High
Summary
Most detailed cardiac safety claims (QT prolongation, torsades risk, hypotension, symptomatology, dose- and condition-related risk) are not supported by the provided FDA label excerpts/citations and include several potentially overextended or ungrounded assertions.
Category Scores
Accurate Statements
Older age may increase susceptibility to lacosamide-related cardiac effects.
Supported by provided label excerpt: 8.5 (greater frequency of increased cardiac conduction abnormalities in elderly; caution with titration).
Taking lacosamide with other medications that can affect the heart (such as antipsychotics or antidepressants) may increase the risk of lacosamide-related cardiac effects.
Partially supported by provided label excerpt: 7.2 (use with caution with concomitant medications that affect cardiac conduction such as beta-blockers/calcium channel blockers/potassium channel blockers and sodium channel blockers). Note: label excerpt does not mention antipsychotics/antidepressants specifically in the provided text.
Renal impairment may increase the risk of lacosamide-related cardiac effects due to accumulation of lacosamide in the body.
Partially supported by provided label excerpt: 2.3 (renal impairment dose guidance), but accumulation rationale is not explicitly present in the provided excerpt.
Unsupported Statements
Lacosamide-related cardiac effects may include QT interval prolongation.
Provided audit results indicate this is absent from the label.
QT interval prolongation associated with lacosamide can increase the risk of torsades de pointes.
Provided audit results indicate this is absent from the label.
Lacosamide-related cardiac effects may include bradycardia.
Marked as only partially supported by audit results (cardiac effects/conduction abnormalities and caution with bradycardia risk in 7.2). The claim as written is not fully supported for specificity but is not flagged as a direct contradiction; treated below as partially supported elsewhere.
Bradycardia associated with lacosamide can lead to symptoms such as dizziness, lightheadedness, and fainting.
Provided audit results indicate this is absent from the label.
Lacosamide-related cardiac effects may include hypotension.
Provided audit results indicate this is absent from the label.
Hypotension associated with lacosamide can cause symptoms such as dizziness, fainting, and decreased blood flow to vital organs.
Provided audit results indicate this is absent from the label.
Pre-existing heart conditions (such as heart failure or arrhythmias) may increase the risk of lacosamide-related cardiac effects.
Provided audit results indicate this is absent from the label.
Higher doses of lacosamide may increase the risk of cardiac effects.
Provided audit results indicate this is absent from the label.
A study in the Journal of Clinical Psychopharmacology found lacosamide was associated with a higher risk of QT interval prolongation compared to other antiepileptic drugs.
Provided audit results indicate this is absent from the label (non-label source).
A study in the European Journal of Clinical Pharmacology found lacosamide was associated with a higher risk of bradycardia and hypotension in patients with epilepsy.
Provided audit results indicate this is absent from the label (non-label source).
The FDA issued a warning in 2018 about the risk of QT interval prolongation associated with lacosamide.
Provided audit results indicate this is absent from the label (non-label source).
The European Medicines Agency (EMA) has issued warnings about the risk of cardiac effects associated with lacosamide.
Provided audit results indicate this is absent from the label (non-label source).
The most common cardiac effects associated with lacosamide include QT interval prolongation, bradycardia, and hypotension.
Provided audit results indicate this is absent from the label.
Older adults, individuals with pre-existing heart conditions, and those taking concomitant medications that can affect the heart may be at increased risk of lacosamide-related cardiac effects.
Partially supported only for older adults and certain conduction-affecting concomitant meds; overall combined claim includes pre-existing heart conditions and other cardiac specifics not supported by provided excerpts/citations.
Regulatory agencies such as the FDA and EMA have issued warnings about the risk of cardiac effects associated with lacosamide.
Provided audit results indicate this is absent from the label (non-label source).
Contradictions
Low
AI Statement
Lacosamide-related cardiac effects may include QT interval prolongation.
Label Reference
Audit indicates absence from provided label excerpts/citations.
Low
AI Statement
Lacosamide-related cardiac effects may include hypotension.
Label Reference
Audit indicates absence from provided label excerpts/citations.
Important Omissions
Specific FDA label-supported monitoring instructions for cardiac conduction abnormalities (e.g., ECG before beginning and after titration to steady-state in patients on concomitant medications affecting cardiac conduction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple detailed cardiac risks (QT prolongation and torsades risk, hypotension and related symptom descriptions, and dose/condition-related risk) are not supported by the provided FDA label excerpts/citations, which could lead to inaccurate risk communication and inappropriate focus without label grounding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several key cardiac safety claims are not supported by the supplied FDA label excerpts/citations, including QT prolongation/torsades and hypotension claims.
Suggested Improvement
Limit claims to those explicitly supported by the provided FDA label excerpts (e.g., cardiac rhythm/conduction abnormalities reference, caution with concomitant conduction-affecting medications and recommended ECG timing, renal impairment dosing guidance, and geriatric caution). Remove non-label-regulatory and journal-study assertions unless the FDA label excerpt explicitly supports them.